Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Promising Early Results For AZ And Daiichi’s Dato-DXd In Breast Cancer – But How Soon Can They File?

Partners Keen To Take On Gilead’s Trodelvy

Executive Summary

Once again choosing their words carefully, the partners talk only of ‘plans’ to file as regulators will first have to clarify when overall survival data will be required for the new antibody-drug conjugate in breast cancer.

You may also be interested in...

ESMO 2023: TROPION-Breast01 And -Lung01 Studies Breathe Life Into Dato-DXd

The future for AstraZeneca/Daiichi Sankyo’s TROP2-targeted ADC candidate Dato-DXd is looking more positive after details of their TROPION-Lung01 and TROPION-Breast01 Phase III studies were presented at ESMO.

AstraZeneca’s Dato-DXd Falls Short Of Great Expectations In Lung Cancer Study

AstraZeneca’s Dato-DXd looks to have so far failed to add a ‘clinically meaningful’ benefit over chemo in the TROPION-Lung01 study, but analysts still expect success for the investigational antibody-drug conjugate.

Gilead’s Trodelvy Basks In TROPiCS With FDA Breast Cancer Nod

Gilead’s big push into oncology bore more fruit with the FDA approval of Trodelvy based on the TROPiCS-02 trial. More development catalysts lie ahead for 2023, company said in its earnings.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts